Mammalian Cell Culture, Biologics:

Market Insight, CDMO Pricing and Competitor Benchmarking

Over 1,000 cumulative hours of qualitative and quantitative data collection and analysis have been utilized to update Nice Insight’s Mammalian Cell Culture, Biologics: Market Insight, CDMO Pricing and Competitor Benchmarking study.

About This Report

• This year we split the 2023 Monoclonal Antibody and Recombinant Protein report by production host, so that we can dive deeper into the production of monoclonal antibodies and the ever-growing antibody-based therapeutic segment.

• We have continued our three-year pricing study and updated the pricing for 2024. We now offer a unique perspective as we can comment on trends in biomanufacturing since 2019.

• This is the first time we dove into the FDA’s clinical trial database to analyze the trends in bispecific antibodies. We discuss trends in the trials, along with top sponsors and top indications being studied.

• We provide projections for ongoing growth of therapeutics entering the clinic and expecting approval, which will drive the need for manufacturing and analytical services.

• We survey the regulatory, technical, and clinical challenges encountered by innovators and manufacturers in this burgeoning market.

• We obtained input from subject matter experts (SMEs) from contract development and manufacturing service providers and buyers of outsourced services.

• We put the manufacturing market in context of ongoing geopolitical news.

Study Methodology

• For the first edition of Nice Insight’s Mammalian Cell Culture, Biologics: Market Insight, CDMO Pricing and Competitor Benchmarking we have focused only on the mammalian-based biologics from our previous reports. We updated all of our trends sections with up-to-date primary, proprietary data and a survey of secondary data from the published literature and industry databases to create a comprehensive outsourced development and manufacturing of biologics in mammalian cells. The quantitative research that we performed is supplemented by direct interviews conducted with multiple SMEs with diverse roles in the sector to obtain qualitative perspectives on the dynamics of the space.

• To build a dataset of bispecific antibody clinical trials, we started with a dataset of every clinical trial published at clinicaltrials.org since January 1, 2013. We probed the dataset in multiple queries to pull out all clinical trials, including building custom macros to mine the data based on drug name, modality, and keywords. We then carefully curated and cleaned the dataset to use in our analysis.

• The data from 490 trials was curated to focus only on the investigation of bispecific antibody, separating them from classical monospecific monoclonal antibodies. This dataset was used to analyze innovators, funding, modalities,  and more.

• The content included here reflects in total over 1,000 hours of dedicated research, interviews, analysis, and composition, both to develop the 2024 pricing study and survey of clinical trials published.

• A team comprising six Ph.D.-level experts collaborated with a group of 25+ existing clients representing CDMOs within the mRNA manufacturing and development sector to probe and better understand benchmarks, current challenges, and the future of the industry.

• Our staff with over 45 years of industry experience worked for over four months to advise on big-picture trends shaping the industry and to unify the data into a holistic view.

• Individual interviews were performed with SMEs representing leadership, manufacturing, innovators, and other operations at small and midsized CDMOs to discuss pricing for contract development and manufacturing services.